Ribena and Lucozade were today sold to the Japanese for £1.3bn — the price of 2.3 billion cartons of the blackcurrant drink. GlaxoSmithKline, Britain’s biggest drugmaker, put the drinks up for sale in February as part of chief executive Sir Andrew Witty’s push on healthcare brands and vaccines. Private equity firms including Blackstone and Lion